4Fonseca V, Desouza C, Asnani S, et al. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev, 2004,25:153-175.
5Wong ND, Kawakubo M, LaBree L, et al. Relation of coronary calcium progression and control of lipids according to National Cholesterol Education Program guidelines. Am J Cardiol, 2004,94:431-436.
6Tuomilehto J. Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia. Diabetes Res Clin Pract, 2003,61(Suppl 1):S27-S34.
7Deedwania PC, Hunninghake DB, Bays H. Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome. Am J Cardiol, 2004,93(Suppl 1):18-26.
8Brown WV. Managing dyslipidaemia multiple patients and multiple approaches: metabolic syndrome, familial hypercholesterolaemia and hypertension. Eur Heart J, 2004,6(Suppl A):A23-A27.
9Aljada A, Ghanim H, Mohanty P, et al. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1(PAI-1) concentrations. J Clin Endocrinol Metab, 2002,87:1419-1422.
10Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol, 2003,92(Suppl 1):18-26.
